News Related to Extensive Stage Small Cell Lung Cancer

Related coverage linked through entity extraction aliases.

CStone Pharmaceuticals Receives FDA Clearance for CS2009 Phase II Trial in Solid Tumors

Feb 16, 2026

CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.

CStone's CS2009 Trispecific Antibody Receives FDA Clearance for Phase II Trial

Feb 16, 2026

CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.